SoCal TBA 有幸邀請到在 Atara Biotherapeutics 擔任執行長的 Cokey Nguyen 博士為今年年會的主題演講嘉賓。

Cokey Nguyen 博士身為細胞治療和癌症治療藥物開發的領航者之一，擁有多年的研究和領導經驗，曾任數個藥廠包含瑞輝、強生的高級主管，帶領雙特性抗體和嵌合抗原受體T細胞療法的研究計畫，並持有多個專利。他於2021年加入 Atara Biotherapeutics，並在今年九月受任為執行長，領導公司發展新一代的細胞治療技術(allogeneic cell therapies)，治療癌症與自體免疫疾病。

這次年會，Cokey Nguyen 博士會將他在生醫業界數十年的經驗濃縮轉化為一場精彩的演講，揭開現今生技製藥的趨勢以及未來發展。千萬不可錯過！

We are thrilled to welcome Dr. Cokey Nguyen, President and CEO of Atara Biotherapeutics, as our keynote speaker this year.

Dr. Nguyen is a leader in the fields of cell therapy and oncology with significant experience in research and development of cell therapies as well as oncology drug discovery and development in biotech. Dr. Nguyen joined Atara in May 2021 as Chief Scientific Officer, where he focused on leading the development of next-generation allogeneic cell therapies for cancer and autoimmune diseases. With his passion for delivering transformative therapies to patients, Dr. Nguyen helped advance Atara’s existing programs and further expanded the pipeline through pioneering science, teamwork, and a commitment to excellence. He was appointed President and Chief Executive Officer and named to the Board of Directors in September 2024.

Prior to joining Atara, Dr. Nguyen was at Fate Therapeutics, where, as Vice President, Innovation, Research and Development, he directed strategy for discovery and innovation efforts, and spearheaded the corporate collaboration program with ONO Pharma. Prior to that, he was leader of the targeted immunotherapy group on the Oncology R&D team at Pfizer, producing bispecific antibodies for solid tumors and hematological malignancies and bringing them into the clinic.

Dr. Nguyen’s bench science experience includes work in tumor metabolism, gene expression and molecular biology. He holds numerous patents for iPSC and immune effector cells and has been published in various peer-reviewed journals. Dr. Nguyen has also been active in successful business development activities, including, while at Janssen, evaluating Legend’s BCMA-directed CAR T program and supporting the Janssen/Legend partnership.

Dr. Nguyen received his undergraduate degree in biology from Harvard College and a Ph.D. in Immunology from Washington University in St. Louis. He was a Postdoctoral Associate at the Center for Cancer Research at the Massachusetts Institute of Technology (MIT), where he focused on the identification and characterization of BRCT domains as novel phosphor-binding domains in DNA damage pathways.

In his free time, Cokey is an avid reader, is a fan of motorsports and enjoys cycling.